Tarsus Pharmaceuticals, Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended September 30, 2021. The unaudited interim financial statements are prepared under U.S. GAAP. Tarsus is a clinical-stage biopharmaceutical company; it had no product sales or approved products.
Financial results
| Metric | Three months ended September 30, 2021 | Nine months ended September 30, 2021 |
|---|---|---|
| Revenue | $1.2 million | $56.7 million |
| Research and development expense | $10.2 million | $33.7 million |
| General and administrative expense | $6.7 million | $18.6 million |
| Net income (loss) | $(15.7) million | $1.0 million |
| Operating cash flow | Not provided for the quarter | $15.9 million |
- Revenue was license fees and collaboration revenue from the China out-license of TP-03 to LianBio, not product sales. Nine-month revenue included $53.1 million of license fees and $3.6 million of collaboration revenue.
- Third-quarter revenue was $1.2 million versus none in 2020; quarterly net loss widened from $10.1 million to $15.7 million. R&D expense rose $2.2 million and G&A expense rose $4.5 million year over year.
- Nine-month results shifted from a $15.3 million loss in 2020 to $1.0 million net income in 2021, largely reflecting China out-license revenue. Operating expenses were $54.4 million, including $2.1 million of costs associated with license and collaboration revenue.
- At September 30, cash and cash equivalents were $183.8 million, versus $168.1 million at December 31, 2020. Total assets were $190.4 million; total liabilities were $11.3 million; stockholders’ equity was $179.1 million. The filing reports no material financing commitments such as lines of credit or guarantees.
- Nine-month investing cash outflow was $0.3 million and financing cash inflow was $0.1 million. Cash increased by $15.7 million, with operating cash inflow primarily reflecting $55 million of China out-license cash receipts during the period.
- The filing does not provide a clear product gross margin or a meaningful product-sales margin; there were no product sales. Interest-rate sensitivity was described as immaterial for a 100-basis-point move.
Business developments and outlook
- TP-03, the lead candidate for Demodex blepharitis, was in Phase 3 development. Saturn-2 enrollment was expected to complete by year-end 2021, with topline results expected in the first quarter of 2022. The company expected to use Saturn-1 and Saturn-2 results to support a planned 2022 NDA submission, subject to positive Saturn-2 results.
- The March 2021 LianBio agreement granted exclusive TP-03 development and commercialization rights in Greater China. Tarsus received $55 million in initial and clinical milestone payments through September 30 and expected a further $15 million in the first half of 2022, subject to achieving a milestone. Additional potential payments include development and regulatory milestones, sales milestones, and tiered royalties; these are contingent, not assured.
- Management estimated existing cash plus expected China-license proceeds would fund operating expenses and capital requirements into the second half of 2023. The filing also states that additional capital will be needed to fully develop the pipeline and execute the strategy, and that future financing may be unavailable or dilutive or restrictive.
- Management expected significant operating expenses and losses to continue as clinical programs advance. No specific revenue or earnings guidance was provided.
- Other pipeline updates included TP-05 entering a Phase 1 study, with data expected in the first half of 2022; TP-04 and additional TP-03 indications remained development programs.
Risks, contingencies, and unusual items
- Key risks include uncertain clinical outcomes and regulatory approval, trial delays or disruption (including potential COVID-19 effects), market acceptance, competition, reliance on third parties and key personnel, and the need for additional capital.
- Quarterly results included a $0.3 million expense from remeasurement of LianBio equity warrant rights; the nine-month remeasurement expense was $1.2 million. The warrants are Level 3 fair-value instruments with significant unobservable valuation inputs.
- R&D included $5.5 million of stock issued to Elanco for expanded lotilaner license rights and a $2.0 million clinical milestone payment. Future Elanco milestones and royalties may also be payable.
- The company reported no material legal proceedings or material changes to the risk factors in its 2020 Form 10-K. Management concluded disclosure controls were effective as of period-end.
Investor verification points
- Confirm the timing and outcome of Saturn-2, and whether results support the anticipated NDA timeline.
- Track receipt and accounting of contingent LianBio milestones, royalties, and future revenue recognition as performance obligations are completed.
- Assess cash burn, the assumptions underlying the stated runway, and potential financing needs and dilution.
- Review clinical, regulatory, manufacturing, and market risks across TP-03, TP-04, and TP-05, along with the valuation assumptions for the LianBio warrants.